This summary was created by AI, based on 12 opinions in the last 12 months.
Cardinal Health Inc (CAH) is the third-largest pharmacy distributor in the USA and has garnered mixed sentiments from various experts. While some appreciate its strong operational streamlining, pricing strategy, and utilization of favorable demographics, others believe it is currently fully valued, with limited upside potential given the stock's recent performance. The company benefits from growth in the healthcare sector, particularly as the aging population increases the demand for pharmaceuticals. However, concerns regarding its growth trajectory, recent contract losses, and the subsequent impact on investor confidence have also been raised. Many experts recommend considering the stock for purchase only during market weakness.
Scores 4/10 on value, 3/10 on fundamentals. Try to avoid. If you're in it and looking for an exit, now's not a bad time because it's had a pop YTD. Only about 4% more upside to analysts' price targets.
She prefers larger, less volatile companies that are a bit more secure. Try UNH or big US pharmaceuticals.
XLV gives you a basket of names, with some winners and some losers. LLY is the top holding, that's a winner. Also holds JNJ and PFE, which haven't done particularly well.
He owns NVO, MCK and CAH. He likes those companies where the only serious competition comes from 1 or 2 others, as they can control pricing power. Diabetes and weight loss are definite growth areas. See his Top Picks.
Recently sold at slight loss, EPS won't have the growth trajectory he thought. Announcement out of left field that they lost a contract and revenue would decline substantially. Reasonably stable business. Over time, will probably be an OK holding. But now market won't have the same confidence in management to execute, stock will be hobbled. He'd look again on further decline.
Distributes pharma and medical products. Largest customer is CVS. Operates in a triopoly, controlling 90% of the US wholesale industry. Pricing power leads to predictable cashflow. Aging population, weight-loss drugs, diabetes treatments will result in higher spending and volume. Shares trending steadily higher, good technical strength. 15% earnings growth going forward. Yield is 1.9%.
(Analysts’ price target is $113.49)Cardinal Health Inc is a OTC stock, trading under the symbol CAH-N on the (). It is usually referred to as or CAH-N
In the last year, 16 stock analysts published opinions about CAH-N. 7 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Cardinal Health Inc.
Cardinal Health Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Cardinal Health Inc.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
16 stock analysts on Stockchase covered Cardinal Health Inc In the last year. It is a trending stock that is worth watching.
On , Cardinal Health Inc (CAH-N) stock closed at a price of $.
9% forecast growth rate, trading ~14x forward PE. Not a bad valuation to growth rate. Great chart of higher highs and higher lows. Outpacing S&P since late 2021. Pricing power and favourable demographics. Yield is 1.6%.